Revenue segments as reported by the company.

Consumer Health

Pharmaceutical

Medical Devices

Innovative Medicine

MedTech

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, marketing and administrative expenses

Research and development expense

In-process research and development

Interest expense

Other expense

Restructuring

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Johnson & Johnson

Band-Aid is a brand name of American pharmaceutical and medical devices giant Johnson & Johnson's line of adhesive bandages.

Band-Aid

Johnson's Baby is an American brand of baby cosmetics and skin care products owned by Johnson & Johnson. The brand dates back to 1893 when Johnson's Baby Powder was introduced. Product line consists of baby powder, shampoos, body lotions, massage oil, shower gels and baby wipes. The brand has reputation for making baby products that are "exceptionally pure and safe" since at least the 1980s.

Johnson's Baby

Aveeno is a brand of skin care and hair care products in the United States owned by American consumer goods and pharmaceutical company Johnson & Johnson. Aveeno was founded in 1945, and its first product was their Soothing Bath Treatment. The active ingredient in all Aveeno products are colloidal oats and/or oat extracts - Avenanthramides, which have been branded as "active naturals". Aveeno offers products to treat skin conditions such as eczema, psoriasis, urushiol-induced contact dermatitis, pruritus ani, chickenpox, hives, and sunburn.

Aveeno

Neutrogena is an American brand of skin care, hair care and cosmetics, that is headquartered in Los Angeles, California. According to product advertising at their website, Neutrogena products are distributed in more than 70 countries. Neutrogena was founded in 1930 by Emanuel Stolaroff, and was originally a cosmetics company named Natone. It is now part of the US-based Johnson & Johnson conglomerate, which bought the independent company in 1994.

Neutrogena

Clean & Clear is a line of dermatology products owned by Johnson & Johnson.

Clean & Clear

Listerine is a brand of antiseptic mouthwash product. It is promoted with the slogan "Kills germs that cause bad breath". Named after Joseph Lister, a pioneer of antiseptic surgery, Listerine was developed in 1879 by Joseph Lawrence, a chemist in St. Louis, Missouri.

Listerine

Acuvue (from "Accurate view") is a brand of disposable contact lenses made by Jacksonville-based Vistakon, a subsidiary of Johnson & Johnson (J&J).

Acuvue

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Johnson & Johnson reports solid Q4 earnings, eyes $60B Pharma revenue

Johnson & Johnson's Q4 2022 showed steady operational growth and strong financial performance. The company aims for continued growth in Pharmaceuticals, focusing on key products and pipeline advancements. Challenges include managing costs, addressing sales declines, and navigating market uncertainties.

Johnson & Johnson reports resilient Q1 performance amidst challenges

Johnson & Johnson's Q1 2023 performance reflects resilience and growth across key segments despite short-term challenges.
The company's strategic focus on innovation, resource management, and portfolio diversification positions it for future success.
While facing legal and financial headwinds, Johnson & Johnson remains optimistic about its outlook for 2023 and beyond.
Increased guidance, product developments, and commitment to safety and innovation underscore the company's long-term growth potential.

Johnson & Johnson reports strong Q2 earnings and strategic growth plans

Johnson & Johnson showcased robust financial results in Q2, raising full-year guidance and highlighting growth in MedTech and Pharmaceuticals. Despite challenges from pricing pressures and litigation, the company remains focused on strategic opportunities and maintaining a strong market position. With a clear focus on innovation and growth, Johnson & Johnson is poised for continued success in the healthcare sector.

Johnson & Johnson posts strong Q3 results amidst growth strategies

Johnson & Johnson (JNJ) delivered robust Q3 results, showcasing growth in sales, earnings, and operational efficiency across key segments, positioning the company for future success.
While facing challenges from geopolitical factors, legal issues, and upcoming competition, JNJ's strategic strengths in acquisitions, innovation, and market presence offer avenues for sustained growth.
With a focus on key brands, pipeline advancements, and MedTech innovations, JNJ remains poised to meet revenue targets, navigate challenges, and capitalize on market opportunities in the coming years.

Johnson & Johnson reports robust 2023 performance and strategic growth outlook

Johnson & Johnson's strong 2023 performance in Innovative Medicine and MedTech drove operational sales growth. Despite inflationary pressures impacting margins, JNJ remains focused on enhancing shareholder returns and pursuing strategic M&A deals. Opportunities for growth in 2024 include new product launches and advancements in key focus areas.

Johnson & Johnson posts strong Q1 earnings, eyes growth opportunities

Johnson & Johnson's Q1 2024 earnings reflect solid performance across key segments, with a focus on innovation and strategic growth initiatives.
Despite challenges in certain segments, the company's proactive approach to restructuring and market dynamics positions it for future success.
Opportunities in Vision Care, Pulmonary Hypertension, and Orthopaedics underscore potential for sustained growth and market leadership.
Overall, Johnson & Johnson's diversified product portfolio and financial outlook support confidence in achieving growth targets for 2024.

Johnson & Johnson posts strong Q2 results, eyes growth opportunities

Johnson & Johnson delivered a robust performance in Q2 2024, driven by strong sales growth in both Innovative Medicine and MedTech segments, supported by strategic initiatives.
While facing challenges in certain markets and the need for continued innovation, the company's outlook remains positive with a solid guidance for the full year 2024.
By capitalizing on opportunities in key products and markets, Johnson & Johnson is well-positioned to navigate challenges and drive sustainable growth in the healthcare sector.

Johnson & Johnson reports robust Q3 earnings amidst legal challenges

Johnson & Johnson's Q3 2024 earnings call showcased strong financial performance, driven by growth in key segments and successful product launches. Despite facing challenges with talc litigation, the company remains focused on innovation, capital allocation, and resolving legal issues.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Johnson & Johnson Inc. JNJ, +0.54% said it lowered its September-ending earnings to account for opioid litigation, according to a Securities and Exchange Commission filing late Wednesday.

Johnson & Johnson restates earnings over opioid settlement

Johnson & Johnson  on Wednesday lowered its previously reported profit for the third quarter to $1.8 billion from $4.8 billion to account for a proposed opioid settlement payment.

Johnson & Johnson says proposed opioid settlement to lower reported third-quarter profit by $3 billion

Teva Pharmaceutical

Walgreens

Don’t play the headlines and don’t make the mistake of lumping all opioid stocks together.

2 Sells and 1 Buy in Opioid Stocks

A previously-unreported deposition could complicate other ongoing litigation.

Report: Johnson & Johnson CEO ‘Believed’ Baby Powder Was Asbestos-Free 13 Days Before FDA Found Trace Levels

JNJ stock while largely flat in terms of performance for the year-to-date has dropped nearly 10% over the past few trading days, bringing it to a well-defined support area. This, coupled with a still attractive dividend yield should get the bulls' attention.

Trade of the Day: Johnson and Johnson Stock’s Dip Is Signal for the Bulls

Facing off against a plaintiff’s lawyer for the first time about Johnson & Johnson’s Baby Powder, the company’s Chief Executive Alex Gorsky earlier this month insisted that the company’s iconic brand was safe.

Johnson & Johnson CEO testified Baby Powder was safe 13 days before FDA bombshell

Johnson & Johnson hasn't been priced at "Fair" or below "Fair" value of P/E 15 since 2013.

Why You Must Look At Fairly-Valued Johnson & Johnson

Even an earnings beat wasn't enough to give the company's share price a big boost.

Johnson & Johnson Hit With an $8 Billion Fine: Has the Stock Become Too Much of a Risk?

Litigation payments will not impact fundamentals. Robust investment in research and development will translate into sales growth and lift JNJ stock for the long haul.

Litigation Dip Is a Buying Opportunity for Johnson and Johnson Stock

Adobe

Applied Materials

These 3 big stock charts highlight big names, and big trends, in a market waiting for direction ahead of earnings season.
The post 3 Big Stock Charts for Tuesday: Johnson & Johnson, Adobe, and Applied Materials appeared first on InvestorPlace.

3 Big Stock Charts for Tuesday: Johnson & Johnson, Adobe, and Applied Materials

Apple

Walmart

There are certain characteristics and reasonings behind stocks that are suitable for investors to buy – and hold – throughout the life of their portfolios.

The 3 Best Stocks to Buy and Hold (Forever)

J&J (JNJ) voluntarily recalls one lot of its baby powders, which is the subject of numerous lawsuits claiming that its talc-based products contain asbestos that causes cancer.

J&J (JNJ) Recalls Baby Powder Batch as FDA Finds Asbestos

Johnson & Johnson (NYSE: JNJ) just can't seem to shake its talcum powder problems.

How Much Litigation Risk Is Priced Into Johnson & Johnson?

Boeing

Coca-Cola

Options trading was buzzing in Johnson & Johnson, Coca-Cola and Boeing on Friday. Here are the metrics that matter moving forward.

Monday’s Vital Data: Johnson & Johnson, Coca-Cola and Boeing

Missteps have hit other Dow stocks, but Johnson and Johnson’s problems are still setting up for big bearish profits as fresh evidence off and on the price chart comes to light
The post Case Closed: Johnson and Johnson Stock Is a Short appeared first on InvestorPlace.
More From InvestorPlace
		
					
				
					2 Toxic Pot Stocks You Should Avoid				
			
					
				
					10 Stocks to Sell Before December’s Meltdown				
			
					
				
					7 Software Stocks to Buy for Growth				
			
					
				
					3 Large-Cap Stocks to Buy After Earnings

Case Closed: Johnson and Johnson Stock Is a Short

I'm raising my fair value estimate for JNJ from $130 to $140.

Don't Overthink It, Buy Johnson & Johnson

W.W. Grainger

Illinois Tool Works

Nucor

Pentair

These members of the “Dividend Aristocrats” have all increased their dividend for at least 25 consecutive years.

5 Stocks Set to Lead Longterm as Fed Rate Cuts Deepen

A recall of its baby powder sparked worries about the healthcare giant's asbestos-related legal battles.

Why Johnson & Johnson Stock Sank Today

American Express

Microsoft

Snap

American Express, Snap, Boeing, Johnson & Johnson and Microsoft were our top stock trades on a busy Friday trading session.

5 Top Stock Trades for Monday: BA, MSFT, JNJ, SNAP, AXP

Atlassian

Atlassian's results aren't good enough, and Johnson & Johnson takes a hit to its reputation.

Stock Market News Today: Oct. 18, 2019

The bad news keeps coming for Johnson & Johnson: The company on Friday announced a voluntary recall of its popular baby powder after some bottles were found to contain small amounts of asbestos.

Johnson & Johnson stock falls after asbestos found in baby powder

Shares of the company’s stock were down nearly 4% Friday morning.

Here’s What Johnson & Johnson Baby Powder Has Been Recalled, And Why

With all of its legal problems, Johnson and Johnson stock is still only 7% away from its highs. It will set new ones soon enough.

Trade Johnson and Johnson Stock to New Highs

Johnson & Johnson is voluntarily recalling a lot of its baby powder after Food and Drug Administration testing detected very low levels of asbestos in a single bottle. JNJ stock plunged.

J&J Stock Plunges After FDA Test Finds Asbestos In Baby Powder

Johnson & Johnson's (NYSE: JNJ) consumer unit will voluntarily recall one lot of Johnson's baby powder “out of an abundance of caution.

News for Johnson & Johnson Stock (JNJ)